Journal ArticleDOI
Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
Gemma Gatta,Laura Botta,Silvia Rossi,Tiiu Aareleid,Magdalena Bielska-Lasota,Jacqueline Clavel,Nadya Dimitrova,Zsuzsanna Jakab,Peter Kaatsch,Brigitte Lacour,Sandra Mallone,Rafael Marcos-Gragera,Pamela Minicozzi,Maria Jose Sanchez-Perez,Milena Sant,Mariano Santaquilani,Charles A. Stiller,Andrea Tavilla,Annalisa Trama,Otto Visser,Rafael Peris-Bonet +20 more
TLDR
The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007.Abstract:
Summary Background Survival and cure rates for childhood cancers in Europe have greatly improved over the past 40 years and are mostly good, although not in all European countries. The EUROCARE-5 survival study estimates survival of children diagnosed with cancer between 2000 and 2007, assesses whether survival differences among European countries have changed, and investigates changes from 1999 to 2007. Methods We analysed survival data for 157 499 children (age 0–14 years) diagnosed between Jan 1, 1978 and Dec 31, 2007. They came from 74 population-based cancer registries in 29 countries. We calculated observed, country-weighted 1-year, 3-year, and 5-year survival for major cancers and all cancers combined. For comparison between countries, we used the corrected group prognosis method to provide survival probabilities adjusted for multiple confounders (sex, age, period of diagnosis, and, for all cancers combined without CNS cancers, casemix). Age-adjusted survival differences by area and calendar period were calculated with period analysis and were given for all cancers combined and the major cancers. Findings We analysed 59 579 cases. For all cancers combined for children diagnosed in 2000–07, 1-year survival was 90·6% (95% CI 90·2–90·9), 3-year survival was 81·0 % (95% CI 80·5–81·4), and 5-year survival was 77·9% (95% CI 77·4–78·3). For all cancers combined, 5-year survival rose from 76·1% (74·4–77·7) for 1999–2001, to 79·1% (77·3–80·7) for 2005–07 (hazard ratio 0·973, 95% CI 0·965–0·982, p Interpretation Several reasons might explain persisting inequalities. The lack of health-care resources is probably most important, especially in some eastern European countries with limited drug supply, lack of specialised centres with multidisciplinary teams, delayed diagnosis and treatment, poor management of treatment, and drug toxicity. In the short term, cross-border care and collaborative programmes could help to narrow the survival gaps in Europe. Funding Italian Ministry of Health, European Commission, Compagnia di San Paolo Foundation.read more
Citations
More filters
Journal ArticleDOI
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
Claudia Allemani,Hannah K. Weir,Helena Carreira,Rhea Harewood,Devon Spika,Xiao-Si Wang,Finian Bannon,Jane V Ahn,Christopher J. Johnson,Audrey Bonaventure,Rafael Marcos-Gragera,Charles A. Stiller,Gulnar Azevedo e Silva,Wanqing Chen,Olufemi Ogunbiyi,Bernard Rachet,Matthew J Soeberg,Hui You,Tomohiro Matsuda,Magdalena Bielska-Lasota,Hans H. Storm,Thomas C. Tucker,Michel P Coleman +22 more
TL;DR: The aim was to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control.
Journal ArticleDOI
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Kristian W. Pajtler,Kristian W. Pajtler,Hendrik Witt,Martin Sill,David T.W. Jones,Volker Hovestadt,Fabian Kratochwil,Khalida Wani,Ruth G. Tatevossian,Chandanamali Punchihewa,Pascal Johann,Jüri Reimand,Hans-Jörg Warnatz,Marina Ryzhova,Steve Mack,Vijay Ramaswamy,David Capper,David Capper,Leonille Schweizer,Leonille Schweizer,Laura Sieber,Andrea Wittmann,Zhiqin Huang,Peter van Sluis,Richard Volckmann,Jan Koster,Rogier Versteeg,Daniel W. Fults,Helen Toledano,Smadar Avigad,Lindsey M. Hoffman,Andrew M. Donson,Nicholas K. Foreman,Ekkehard Hewer,Karel Zitterbart,Mark R. Gilbert,Terri S. Armstrong,Terri S. Armstrong,Nalin Gupta,Jeffrey C. Allen,Matthias A. Karajannis,David Zagzag,Martin Hasselblatt,Andreas E. Kulozik,Olaf Witt,V. Peter Collins,Katja von Hoff,Stefan Rutkowski,Torsten Pietsch,Gary D. Bader,Marie-Laure Yaspo,Andreas von Deimling,Andreas von Deimling,Peter Lichter,Michael D. Taylor,Richard J. Gilbertson,David W. Ellison,Kenneth Aldape,Andrey Korshunov,Andrey Korshunov,Marcel Kool,Stefan M. Pfister +61 more
TL;DR: The molecular classification proposed herein outperforms the current histopathological classification and thus might serve as a basis for the next World Health Organization classification of CNS tumors.
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,D. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C. Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,Diana A. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
Barbara C. Worst,Barbara C. Worst,Cornelis M. van Tilburg,Gnana Prakash Balasubramanian,Petra Fiesel,Petra Fiesel,Ruth Witt,Angelika Freitag,Miream Boudalil,Miream Boudalil,Christopher Previti,Stephan Wolf,Sabine Schmidt,Sasithorn Chotewutmontri,Melanie Bewerunge-Hudler,Matthias Schick,Matthias Schlesner,Barbara Hutter,Lenka A. Taylor,Tobias Borst,Christian Sutter,Claus R. Bartram,Till Milde,Till Milde,Elke Pfaff,Elke Pfaff,Andreas E. Kulozik,Arend von Stackelberg,Roland Meisel,Arndt Borkhardt,Dirk Reinhardt,Jan-Henning Klusmann,Gudrun Fleischhack,Stephan Tippelt,Uta Dirksen,Heribert Jürgens,Christof M. Kramm,André O. von Bueren,Frank Westermann,Matthias Fischer,Matthias Fischer,Birgit Burkhardt,Wilhelm Wößmann,Michaela Nathrath,Stefan S. Bielack,Michael C. Frühwald,Simone Fulda,Thomas Klingebiel,Ewa Koscielniak,Matthias Schwab,Matthias Schwab,Roman Tremmel,Roman Tremmel,Pablo Hernáiz Driever,Johannes H. Schulte,Benedikt Brors,Andreas von Deimling,Andreas von Deimling,Peter Lichter,Angelika Eggert,David Capper,David Capper,Stefan M. Pfister,Stefan M. Pfister,David T.W. Jones,Olaf Witt,Olaf Witt +66 more
TL;DR: This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients and expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine.
References
More filters
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal ArticleDOI
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
Book
Cancer Incidence in Five Continents
Freddie Bray,J. Ferlay,Mathieu Laversanne,David H. Brewster,C. Gombe Mbalawa,B. Kohler,Marion Piñeros,Eva Steliarova-Foucher,Rajaraman Swaminathan,Sebastien Antoni,Isabelle Soerjomataram,David Forman +11 more
TL;DR: The aim of this study was to establish a database of histological groups and to provide a level of consistency and quality of data that could be applied in the design of future registries.
Journal ArticleDOI
International Statistical Classification of Diseases and Related Health Problems
TL;DR: There is substantial global variation in the relative burden of stroke compared with IHD, and the disproportionate burden from stroke for many lower-income countries suggests that distinct interventions may be required.